Alkermes plc.
For the period ended Dec 31, 2025. Filed Feb 25, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Feb 25, 2026
ALKS$46.17+0.6%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Shareholders’ Equity
| Accumulated | ||||||||
|---|---|---|---|---|---|---|---|---|
| Additional · Other | ||||||||
| Ordinary Shares · Paid-In · Comprehensive · Accumulated · Treasury Stock | ||||||||
| Shares | Amount | Capital | Loss | Deficit | Shares | Amount | Total | |
| (In thousands, except share data) | ||||||||
| BALANCE — December 31, 2022 | 168,951,193 | $1,690 | $2,913,099 | $(10,889) | $(1,699,285) | (4,574,184) | $(160,862) | $1,043,753 |
| Issuance of ordinary shares under employee stock plans | 3,617,858 | 36 | 16,724 | — | — | — | — | 16,760 |
| Receipt of Alkermes' ordinary shares for the purchase of stock options or to satisfy minimum tax withholding obligations related to share-based awards | — | — | — | — | — | (1,015,034) | (28,474) | (28,474) |
| Share-based compensation | — | — | 100,871 | — | — | — | — | 100,871 |
| Unrealized gain on marketable securities, net of tax provision of $1,195 | — | — | — | 7,779 | — | — | — | 7,779 |
| Distribution of Mural Oncology plc | — | — | (293,760) | — | — | — | — | (293,760) |
| Net income | — | — | — | — | 355,757 | — | — | 355,757 |
| BALANCE — December 31, 2023 | 172,569,051 | $1,726 | $2,736,934 | $(3,110) | $(1,343,528) | (5,589,218) | $(189,336) | $1,202,686 |
| Issuance of ordinary shares under employee stock plans | 4,101,734 | 41 | 27,531 | — | — | — | — | 27,572 |
| Receipt of Alkermes' ordinary shares for the purchase of stock options or to satisfy minimum tax withholding obligations related to share-based awards | — | — | — | — | — | (1,010,156) | (29,637) | (29,637) |
| Repurchase of Alkermes' ordinary shares | — | — | — | — | — | (7,894,417) | (200,282) | (200,282) |
| Share-based compensation | — | — | 96,425 | — | — | — | — | 96,425 |
| Unrealized gain on marketable securities, net of tax provision of $292 | — | — | — | 1,143 | — | — | — | 1,143 |
| Net income | — | — | — | — | 367,070 | — | — | 367,070 |
| BALANCE —December 31, 2024 | 176,670,785 | $1,767 | $2,860,890 | $(1,967) | $(976,458) | (14,493,791) | $(419,255) | $1,464,977 |
| Issuance of ordinary shares under employee stock plans | 4,340,381 | 43 | 43,368 | — | — | — | — | 43,411 |
| Receipt of Alkermes' ordinary shares for the purchase of stock options or to satisfy minimum tax withholding obligations related to share-based awards | — | — | — | — | — | (910,347) | (31,032) | (31,032) |
| Repurchase of Alkermes' ordinary shares | — | — | — | — | — | — | — | — |
| Share-based compensation | — | — | 100,408 | — | — | — | — | 100,408 |
| Unrealized loss on marketable securities, net of tax benefit of $55 | — | — | — | (133) | — | — | — | (133) |
| Net income | — | — | — | — | 241,664 | — | — | 241,664 |
| BALANCE —December 31, 2025 | 181,011,166 | $1,810 | $3,004,666 | $(2,100) | $(734,794) | (15,404,138) | $(450,287) | $1,819,295 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.